PL2011486T5 - Farmaceutyczne kompozycje rifaksyminy - Google Patents

Farmaceutyczne kompozycje rifaksyminy

Info

Publication number
PL2011486T5
PL2011486T5 PL08252198.0T PL08252198T PL2011486T5 PL 2011486 T5 PL2011486 T5 PL 2011486T5 PL 08252198 T PL08252198 T PL 08252198T PL 2011486 T5 PL2011486 T5 PL 2011486T5
Authority
PL
Poland
Prior art keywords
rifaximin
pharmaceutical compositions
pharmaceutical
compositions
Prior art date
Application number
PL08252198.0T
Other languages
English (en)
Other versions
PL2011486T3 (pl
Inventor
Harshal Anil Jahagirdar
Rajesh Kulkarni
Shirishkumar Kulkarni
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40091777&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2011486(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of PL2011486T3 publication Critical patent/PL2011486T3/pl
Publication of PL2011486T5 publication Critical patent/PL2011486T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
PL08252198.0T 2007-07-06 2008-06-26 Farmaceutyczne kompozycje rifaksyminy PL2011486T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN968KO2007 2007-07-06
EP08252158 2008-06-23
EP08252198.0A EP2011486B2 (en) 2007-07-06 2008-06-26 Pharmaceutical compositions of rifaximin

Publications (2)

Publication Number Publication Date
PL2011486T3 PL2011486T3 (pl) 2013-01-31
PL2011486T5 true PL2011486T5 (pl) 2016-09-30

Family

ID=40091777

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08252198.0T PL2011486T5 (pl) 2007-07-06 2008-06-26 Farmaceutyczne kompozycje rifaksyminy

Country Status (8)

Country Link
EP (4) EP2011486B2 (pl)
CY (1) CY1113068T1 (pl)
DK (1) DK2011486T3 (pl)
ES (3) ES2905795T3 (pl)
HR (1) HRP20120665T1 (pl)
PL (1) PL2011486T5 (pl)
PT (1) PT2011486E (pl)
SI (1) SI2011486T1 (pl)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20032144A1 (it) 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
US7906542B2 (en) 2004-11-04 2011-03-15 Alfa Wassermann, S.P.A. Pharmaceutical compositions comprising polymorphic forms α, β, and γ of rifaximin
US7902206B2 (en) 2003-11-07 2011-03-08 Alfa Wassermann, S.P.A. Polymorphic forms α, β and γ of rifaximin
ES2522895T3 (es) 2005-03-03 2014-11-19 Alfa Wassermann S.P.A. Nuevas formas polimorfas de rifaximina, procedimientos para su producción y uso de las mismas en preparados medicinales
ITBO20050123A1 (it) 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
EP2942053A1 (en) * 2007-07-06 2015-11-11 Lupin Limited Pharmaceutical compositions for gastrointestinal drug delivery
US7928115B2 (en) 2008-10-02 2011-04-19 Salix Pharmaceuticals, Ltd. Methods of treating travelers diarrhea and hepatic encephalopathy
BRPI0920465A2 (pt) 2008-10-02 2018-03-20 Salix Pharmaceuticals, Inc. metodo de tratamento de encefalopatia hepática
US20110035232A1 (en) 2008-10-02 2011-02-10 Salix Pharmaceuticals, Ltd. Methods of treating hepatic encephalopathy
WO2010148040A1 (en) * 2009-06-15 2010-12-23 Salix Pharmaceuticals, Ltd. Modulation of systemic exposure to rifaximin
RU2012121599A (ru) * 2009-10-27 2013-12-10 Люпин Лимитед Твердая дисперсия рифаксимина
US9018684B2 (en) 2009-11-23 2015-04-28 California Institute Of Technology Chemical sensing and/or measuring devices and methods
IT1398550B1 (it) 2010-03-05 2013-03-01 Alfa Wassermann Spa Formulazioni comprendenti rifaximina utili per ottenere un effetto prolungato nel tempo
CN103228662B (zh) 2010-07-12 2016-08-10 萨利克斯药品有限公司 利福昔明的制剂及其用途
ITBO20110461A1 (it) 2011-07-29 2013-01-30 Alfa Wassermann Spa Composizioni farmaceutiche comprendenti rifaximina, processi per la loro preparazione e loro uso nel trattamento di infezioni vaginali.
ITBO20120368A1 (it) 2012-07-06 2014-01-07 Alfa Wassermann Spa Composizioni comprendenti rifaximina e amminoacidi, cristalli di rifaximina derivanti da tali composizioni e loro uso.
WO2014033077A1 (en) 2012-08-28 2014-03-06 Dsm Sinochem Pharmaceuticals Netherlands B.V. Composition comprising an antibiotic and a beta-lactamase inhibitor, wherein at| least one of them is in the form of mini-tablets
EP2927235B1 (en) * 2014-03-31 2017-02-08 Euticals S.P.A. Polymorphic mixture of rifaximin and its use for the preparation of solid formulations
WO2015173697A1 (en) 2014-05-12 2015-11-19 Alfa Wassermann S.P.A. New solvated crystal form of rifaximin, production, compositions and uses thereof
EP4137132A1 (en) * 2016-09-30 2023-02-22 Salix Pharmaceuticals, Inc. Solid dispersion forms of rifaximin
MX2018010065A (es) 2017-04-26 2019-02-07 Sandoz Ag Forma de dosificacion oral que comprende rifaximina en forma beta.
US11129862B2 (en) * 2017-08-30 2021-09-28 Johnson & Johnson Consumer Inc. Ophthalmic compositions
CN108658673A (zh) * 2018-06-27 2018-10-16 安徽瑞然生物药肥科技有限公司 一种用于缓释肥料的包膜材料及其制备方法
CN109021187B (zh) * 2018-08-24 2019-09-06 中山大学 玉米醇溶蛋白-聚磺基甜菜碱两亲性缀合物及其制备方法与应用
CN109663150B (zh) * 2018-12-29 2022-01-14 广州贝奥吉因生物科技股份有限公司 一种心肌修复水凝胶材料及其制备方法
WO2020208140A1 (en) 2019-04-12 2020-10-15 Sandoz Ag Rifaximin-containing granules
JP2022548788A (ja) * 2019-09-24 2022-11-21 バウシュ ヘルス アイルランド リミテッド リファキシミン液体製剤
CN111317824B (zh) * 2020-02-29 2022-04-12 复旦大学 一种载多肽药物的口服纳米制剂及其制备方法
AU2021298178A1 (en) * 2020-06-26 2023-02-02 Bausch Health Ireland Limited Targeted release rifaximin compositions
WO2023067485A1 (en) * 2021-10-19 2023-04-27 Zydus Lifesciences Limited Pharmaceutical combinations

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1154655B (it) 1980-05-22 1987-01-21 Alfa Farmaceutici Spa Derivati imidazo-rifamicinici metodi per la loro preparazione e loro uso come sostanza ad azione antibatterica
IT1253711B (it) * 1991-12-17 1995-08-23 Alfa Wassermann Spa Formulazioni farmaceutiche vaginali contenenti rifaximin e loro uso nel trattamento delle infezioni vaginali
IT1264494B1 (it) † 1993-03-23 1996-09-24 Alfa Wassermann Spa Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter
ITMI20032144A1 (it) * 2003-11-07 2005-05-08 Alfa Wassermann Spa Forme polimorfe di rifaximina, processi per ottenerle e
ITMI20041295A1 (it) † 2004-06-25 2004-09-25 Cosmo Spa Composizioni farmaceutiche antimicrobiche orali
US20060045865A1 (en) † 2004-08-27 2006-03-02 Spherics, Inc. Controlled regional oral delivery
ITBO20050123A1 (it) * 2005-03-07 2005-06-06 Alfa Wassermann Spa Formulazioni farmaceutiche gastroresistenti contenenti rifaximina

Also Published As

Publication number Publication date
EP2011486A1 (en) 2009-01-07
EP3714878A1 (en) 2020-09-30
EP2420226B1 (en) 2020-03-04
SI2011486T1 (sl) 2012-10-30
ES2389358T3 (es) 2012-10-25
CY1113068T1 (el) 2016-04-13
DK2011486T3 (da) 2012-09-03
ES2905795T3 (es) 2022-04-12
ES2389358T5 (es) 2016-01-19
EP2011486B2 (en) 2015-08-12
HRP20120665T1 (hr) 2012-10-31
EP2420226A1 (en) 2012-02-22
EP2837378A1 (en) 2015-02-18
EP3714878B1 (en) 2022-01-19
PT2011486E (pt) 2012-08-24
EP2011486B1 (en) 2012-05-23
ES2798253T3 (es) 2020-12-10
PL2011486T3 (pl) 2013-01-31

Similar Documents

Publication Publication Date Title
ZA201000437B (en) Pharmaceutical compositions of rifaximin
SI2011486T1 (sl) Farmacevtski sestavki rifaksimina
IL247741A0 (en) pharmaceutical preparations
ZA200900347B (en) Preparation of pharmaceutical compositions
EP2222313A4 (en) PHARMACEUTICAL COMPOSITIONS
ZA200905134B (en) Compositions of stable tiacumicins
GB0610322D0 (en) Novel pharmaceutical compositions
GB0608724D0 (en) Novel Pharmaceutical Compositions
PT2966175T (pt) Composições farmacêuticas contendo 17-alfa-propionato de cortexolona
EP2146695A4 (en) PHARMACEUTICAL COMPOSITIONS
GB0709811D0 (en) Pharmaceutical compositions
SI2002825T1 (sl) Farmacevtski sestavki, ki obsegajo orlistat
GB0707127D0 (en) Pharmaceutical compositions
GB0716907D0 (en) Pharmaceutical powder compositions
GB0712454D0 (en) Pharmaceutical compositions
GB2454923B (en) Pharmaceutical compositions
IL201394A0 (en) Niacin - based pharmaceutical compositions
HU0700755D0 (en) Pharmaceutical compositions containing capsaicionid
GB0704749D0 (en) Novel pharmaceutical compositions
GB0713794D0 (en) Novel pharmaceutical compositions
GB0701364D0 (en) Novel pharmaceutical compositions
GB0701367D0 (en) Novel pharmaceutical compositions
GB0701368D0 (en) Novel pharmaceutical compositions
GB0709603D0 (en) Pharmaceutical compositions
GB0706657D0 (en) Pharmaceutical compositions